 |
|
Well-tolerated for successful starts in ART-naive patients: All grade 2-4 drug-related AEs were < 10%
|
APV30002 (SOLO) a randomized, open-label study of LEXIVA/r (1400/200 mg) QD vs NFV (1250 mg) BID in combination with ABC/3TC BID in 649 ART-naive patients.
|
|
• No jaundice or scleral icterus1
|
Well-tolerated for successful starts in ART-naive patients: All grade 2-4 drug-related AEs were < 10%
|
APV30001 (NEAT) a randomized, open-label study of LEXIVA (1400 mg) BID vs NFV (1250 mg) BID in combination with ABC/3TC BID in 249 ART-naive patients.
|
|
• No jaundice or scleral icterus1
|
Well-tolerated in PI-experienced patients: All grade 2-4 drug-related AEs were < 13%
| • |
Most common grade 2-4 drug-related AEs in PI-experienced patients were diarrhea, headache, nausea, rash, and vomiting
Reference: 1. Data on file, GlaxoSmithKline.
|
|
